Why the study?
Do new anticoagulants (enoxaparin, fondaparinux, bivalirudin) improve outcomes compared to unfractionated heparin in patients with NSTE-ACS undergoing PCI?
Do new anticoagulants (enoxaparin, fondaparinux, bivalirudin) improve outcomes compared to unfractionated heparin in patients with NSTE-ACS undergoing PCI?
Answers are grounded in this paper and cite their sources.
Newer anticoagulants offer alternatives to UFH in NSTE-ACS patients undergoing PCI, but their specific limitations regarding safety, cost, and efficacy require careful consideration.
Unfractionated heparin (UFH) has long been the only thrombin inhibitor used in non ST-elevation ACS (NSTE-ACS) patients undergoing percutaneous coronary intervention. Better anticoagulation regimens have been developed given the limitations of UFH which include its sometimes difficult-to-manage effects on coagulation, the need for repeated monitoring of coagulation, the narrow therapeutic window, the potential induction of platelet activation, and the risk of thrombocytopenia. The three new anticoagulants, enoxaparin, fondaparinux, and bivalirudin have demonstrated improvements, against UFH and represent new alternative therapies. We have reviewed the major challenges for each of them to become ideal. Additional data are needed for enoxaparin when accumulation of the drug is likely to occur (obese patients, renal insufficiency) given the risk of subsequent bleeding. Fondaparinux and bivalirudin represent an opportunity to improve safety. However, cost is a real concern for bivalirudin especially when access to the catheterization laboratory is delayed. In addition, whether bivalirudin can replace selective procedural abciximab use in the catheterization laboratory in high-risk ACS patients also remains to be established. Catheter thrombosis is a concern for fondaparinux and the need for combining UFH with fondaparinux to overcome this potential detrimental side effect is an unexpected limitation that needs re-appraisal.
No takes yet. Share an insight, caveat, or question.
Collet et al. (2007) conducted a review in Non-ST-elevation acute coronary syndromes (NSTE-ACS) undergoing percutaneous coronary intervention. Enoxaparin, fondaparinux, and bivalirudin vs. Unfractionated heparin (UFH) was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: